Last reviewed · How we verify
Amitryptiline
At a glance
| Generic name | Amitryptiline |
|---|---|
| Also known as | Tryptizol, Laroxyl |
| Sponsor | Mahatma Gandhi Institute of Medical Sciences |
| Target | Aldehyde oxidase, 5-hydroxytryptamine receptor 6, D(1B) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Depressive disorder
- Mixed anxiety and depressive disorder
Common side effects
Key clinical trials
- Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS) (PHASE3)
- Quality Improvement and Practice Based Research in Neurology Using the EMR (PHASE4)
- Trial Evaluating multimOdal toPical Cream In CompArison to pLacebo (TOPICAL) (PHASE2, PHASE3)
- Low Doses Amitriptyline & Chronic Neck Pain (PHASE4)
- Trial of the Treatment of Chronic Laryngitis With Amitryptiline (PHASE2, PHASE3)
- Treatment of Ilioinguinal Entrapment Syndrome - an Often Overlooked Cause of Chronic Pelvic Pain (NA)
- Anti-Depressants vs Physiotherapy in Management of Fibromyalgia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amitryptiline CI brief — competitive landscape report
- Amitryptiline updates RSS · CI watch RSS
- Mahatma Gandhi Institute of Medical Sciences portfolio CI